New analysis of zuranolone efficacy and safety

20 September 2022

Sage Therapeutics (Nasdaq: SAGE) closed up 3.8% at $42.14 on Tuesday after, along with partner Biogen (Nasdaq: BIIB), it announced new analyses from across the development program for zuranolone.

The investigational, oral, once-daily, 14-day treatment is in clinical development for adults with major depressive disorder (MDD) and postpartum depression (PPD).

"Rapid and sustained improvement in depressive symptoms"An analysis from the ongoing open-label, longitudinal SHORELINE study in MDD found the median time to the first repeat treatment course for those patients who responded to the initial 14-day treatment course was 135 days for the completed 30mg arm and 249 days for the ongoing 50mg cohort.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK